Videos Library

Event Videos

PharmAccess Leaders Forum (Autumn)

October 13-15, 2015

HTA, funding & reimbursement of cell & gene therapies: A global perspective

Related topics: Pharmaceutical/Biotech, Market Access & HEOR, Global (non-specific)
Availability: FREE
  • Health technology assessment challenges in assessing clinical and cost effectiveness of cell / gene therapies.
  • Who pays? Healthcare system determinants of funding/reimbursement paradigm.
  • Affordability: Pricing and budget impact challenges

W. Neil Palmer
President & Principal Consultant
PDCI Market Access Inc.


Central and Eastern Europe: Diversity to tame, market access potential to unveil

Related topics: Pharmaceutical/Biotech, MedTech, Europe, Market Access & HEOR, Central Eastern Europe
Availability: FREE
  • Regional diversities in approaches to public funding decision making.
  • Comparative measures to enable informed allocation of company strategic efforts.
  • Analysis of public funding decision making practice as a tool to identify risks and opportunities and to provide unbeatable arguments to CEE decision makers

Norbert Wilk
Director, Market Access Consulting
Arcana Institute, Poland


Devising value-enhancing strategies for biosimilars: A conceptual framework

Related topics: Pharmaceutical/Biotech, Market Access & HEOR, Biosimilars
Availability: FREE
  • Is differentiation possible or even necessary in the biosimilars market? Although the impetus for a biosimilar development originally might have been solely economic, we argue thatmmanufacturers should devise a value proposition for biosimilars that moves beyond price, demonstrating value to payers, physicians, and patients.
  • Presenting a unifying value framework as a guiding tool for biosimilar manufacturers supporting internal processes - for example: Building internal business cases for differentiating concepts with the end goal to develop a value-enhancing strategy.

Sotiris Rompas
Boston Healthcare, USA


Biologics, biosimilars, and interchangeable biologics: US update after first launch

Related topics: Pharmaceutical/Biotech, USA, Market Access & HEOR, Biosimilars
Availability: FREE
  • The US is essentially a “secondary” market for biosimilars; as such, what can be learned from other markets?
  • The business model for biosimilars, neither branded or generic products, is likely to be different in the US than in other markets, especially when it comes to pricing. How will business models be structured and operate?
  • With only 5 applications and 1 approval to date, there isn’t yet a clear regulatory pathway for biosimilars in the US. What might that pathway look like when more fully developed?
  • With originators of branded products making more defensive manoeuvres in the US than in other countries, lifecycle management of biosimilars is likely to be different in the US than elsewhere. What differences will there be?

Kathleen E. Hughes
Vice President, Avalere Health, USA


Blueprint for market access: Strategic insights from the regulatory and HTA review process

Related topics: Pharmaceutical/Biotech, Europe, Market Access & HEOR
Availability: FREE

An interactive session exploring the lifecycle of a drug including:

  • Comparison of regulatory and HTA agency clinical trial evaluations
  • Impact of the label indications on the HTA review process
  • HTA opinion on submitted evidence

Yin Ho
Context Matters Inc., USA